Intervention not reported
10‐year overall survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 10‐year overall survival rate (5 to 15 yr) (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year disease specific survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 5‐year disease specific survival rate (5 to 15 yr) (moderate certainty).
1 finding from 1 review
Intervention not reported
10‐year disease specific survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 10‐year disease specific survival rate (5 to 15 yr) (moderate certainty).
1 finding from 1 review
Intervention not reported
3‐year relapse‐free survive rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 3‐year relapse‐free survive rate (37.2/40.2 mo) (low certainty).
1 finding from 1 review
Intervention not reported
5‐year relapse‐free survive rate (66 mo) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 5‐year relapse‐free survive rate (66 mo) (low certainty).
1 finding from 1 review
Intervention not reported
3‐year local control rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 3‐year local control rate (37.2/40.2 mo) (low certainty).
1 finding from 1 review
Intervention not reported
5‐year local control rate (3 to 6 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 5‐year local control rate (3 to 6 yr) (low certainty).
1 finding from 1 review
Intervention not reported
Recurrence rate at 1 year · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall Survival (median · Patients with brain metastases
The intervention showed no clear difference in overall Survival (median (low certainty).
1 finding from 1 review
Intervention not reported
Progression free survival · Patients with brain metastases
The intervention showed no clear difference in progression free survival (low certainty).
1 finding from 1 review
Intervention not reported
Any intracranial disease progression at 1 year · Patients with brain metastases
The intervention may leads to lower any intracranial disease progression at 1 year (low certainty).
1 finding from 1 review
Intervention not reported
Neurocognitive function · Patients with brain metastases
1 finding from 1 review
Intervention not reported
Health related quality of life · Patients with brain metastases
1 finding from 1 review
Intervention not reported
Adverse events · Patients with brain metastases
1 finding from 1 review
Complete resection ‐ iMRI · high‐grade glioma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
5‐ year OS · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention probably leads to lower 5‐ year OS (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year PFS · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention probably leads to lower 5‐year PFS (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year OS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention showed no clear difference in 5‐year OS (stage III) (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year PFS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention showed no clear difference in 5‐year PFS (stage III) (moderate certainty).
1 finding from 1 review
Intervention not reported
PFS (stage III/IV) Median · women with advanced (stage III/IV) endometrial cancer after surgery and radiotherapy
The intervention showed no clear difference in PFS (stage III/IV) Median (moderate certainty).
1 finding from 1 review